AmCORE Study: Treatment Patterns and Survival Across Age Groups in Colorectal Liver Metastases

AmCORE Study: Treatment Patterns and Survival Across Age Groups in Colorectal Liver Metastases

Colorectal cancer (CRC) is increasingly being diagnosed in adults younger than 50 years, raising questions about whether younger patients require different treatment approaches and whether their outcomes differ from those of older patients. This is particularly relevant for patients with colorectal liver metastases (CRLM), where both systemic therapy and liver-directed treatments play important roles.

Surgical resection and thermal ablation offer potentially curative options for selected patients with CRLM, while systemic treatment may be used before local therapy to reduce disease burden or address unfavorable prognostic features. However, treatment recommendations are largely informed by studies involving patients aged 50–70 years, with younger and older populations less well represented.

A study titled “Differences in Treatment and Outcomes Between Young and Older Patients With Colorectal Cancer Liver Metastases: An AmCORE-Based Study,” published online on November 9, 2026, in ESMO Gastrointestinal Oncology, examined how treatment strategies and survival outcomes differ across age groups among patients undergoing local treatment for CRLM.

Authors: Janneke F. E. Vedder, Hannah H. Schulz, Rutger-Jan Swijnenburg, Martijn R. Meijerink, Kathelijn S. Versteeg, and Tineke E. Buffart.

Study Design

This retrospective cohort study included 351 patients from the Amsterdam Colorectal Cancer Liver Metastases Registry (AmCORE) who underwent their first local treatment for CRLM between January 2018 and December 2023. Patients were divided into three age groups: 31 patients (8.8%) were younger than 50 years (early-onset CRC), 164 (46.7%) were aged 50–69 years (average-onset CRC), and 156 (44.4%) were aged 70 years or older (late-onset CRC).

The primary endpoint was progression-free survival (PFS), measured from the first local treatment of CRLM to disease recurrence, including recurrence of treated liver metastases or the development of new hepatic or extrahepatic lesions. Overall survival (OS), measured from the diagnosis of the first liver metastases, was the secondary endpoint. The study also examined systemic and local treatment patterns and factors associated with the use of induction systemic therapy.

PUMP at ASCO 2026

Treatment Patterns Across Age Groups

Disease presentation and treatment patterns differed across the three age groups. Patients younger than 50 years had a higher number of liver metastases at diagnosis, with a median of four lesions compared with two in both the 50–69 and ≥70-year groups (P = 0.030). Synchronous liver metastases were also more frequent among younger patients, occurring in 71%, compared with 55.5% of patients aged 50–69 years and 53.2% of those aged ≥70 years (P = 0.027).

These differences were accompanied by greater use of systemic treatment among younger patients. Across the entire disease course, systemic therapy was administered to 87.1% of patients younger than 50 years, compared with 72.6% and 45.5% in the average-onset and late-onset groups, respectively (P < 0.001).

A similar pattern was observed for induction systemic therapy before the first local treatment of CRLM. Induction treatment was administered to 58.1% of patients younger than 50 years, compared with 40.5% of those aged 50–69 years and 21.8% of patients aged ≥70 years (P < 0.001).

Among patients receiving induction systemic therapy, triplet chemotherapy with fluorouracil, oxaliplatin, and irinotecan, with or without bevacizumab, was administered to 21.1% of younger patients, 25.8% of those aged 50–69 years, and 8.8% of patients aged ≥70 years (P = 0.007). Despite these differences in systemic treatment, the type of first local treatment, including surgical resection, thermal ablation, or combined procedures, did not differ significantly between age groups (P = 0.174).

Further analysis showed that both the number of liver metastases (OR 1.56; 95% CI 1.36–1.82) and the diameter of the largest metastasis (OR 1.02; 95% CI 1.00–1.05) were significantly associated with the likelihood of receiving induction systemic treatment (both P < 0.001).

Progression-Free and Overall Survival

Despite receiving more intensive systemic treatment, younger patients did not experience better survival outcomes. At a median PFS follow-up of 31.1 months, the median PFS in the overall cohort was 6.6 months (95% CI 5.7–7.6).

PFS differed significantly across age groups, with shorter PFS observed in patients younger than 50 years (P = 0.019). When outcomes were analyzed according to induction treatment, median PFS was 5.6 months (95% CI 4.6–7.0) among patients who received induction chemotherapy, compared with 7.4 months (95% CI 6.0–9.1) among those who did not (P = 0.022).

However, the investigators emphasized that this association should be interpreted cautiously, as patients selected for induction treatment generally presented with a greater burden of liver metastases. For OS, the median follow-up was 40.2 months, and the median OS of the entire cohort was 54.3 months (95% CI 50.8–not estimable). The estimated survival rates were 96.1% at one year, 70.2% at three years, and 44.6% at five years.

Importantly, OS did not differ significantly across the three age groups (P = 0.22), despite substantial differences in treatment intensity. Similarly, median OS was 51.2 months in patients who received induction systemic treatment compared with 59.0 months in those who did not, without a statistically significant difference (P = 0.66).

In a propensity-score–weighted sensitivity analysis comparing patients aged 50–69 years with those aged ≥70 years, neither age group nor induction systemic treatment was significantly associated with OS.

Find more videos on OncoDaily YouTube TV.

What Could Explain These Differences?

Differences in disease presentation may help explain the shorter PFS observed in younger patients. Patients younger than 50 years were more likely to have synchronous metastases and a higher number of liver lesions at diagnosis, both of which are associated with recurrence risk.

The investigators proposed that greater disease burden at presentation, potentially related to delayed diagnosis, may partly explain why younger patients experienced shorter PFS despite more intensive treatment. However, the study could not establish whether these differences were related to delayed detection, tumor biology, or other clinical factors.

Older patients, meanwhile, more frequently presented with metachronous liver metastases and fewer lesions. These differences may help explain why OS remained comparable despite less frequent use of systemic therapy. The authors also acknowledged that the study could not determine whether the lower treatment intensity observed in older patients reflected appropriate clinical selection or possible undertreatment.

Several limitations should be considered. The analysis was retrospective and conducted at a single tertiary referral center, with only 31 patients younger than 50 years. Additionally, the registry included only patients selected for local treatment of CRLM, limiting the generalizability of the findings to the broader metastatic CRC population.

Incomplete molecular profiling, particularly among older patients, and the absence of systematic geriatric assessment further limited the interpretation of treatment decisions and outcomes.

Takeaway

This AmCORE-based study found that patients younger than 50 years with colorectal liver metastases received more intensive systemic therapy but experienced shorter PFS, while OS did not differ significantly across age groups.

The findings suggest that greater disease burden at diagnosis may contribute to poorer PFS among younger patients, although differences in tumor biology and other factors cannot be excluded.

Importantly, the results do not establish that more intensive treatment worsens outcomes or that less intensive treatment is equally effective. Rather, they highlight the importance of considering disease characteristics, molecular features, patient fitness, and treatment goals when making decisions for patients with CRLM, instead of relying on chronological age alone.

The full article is available in ESMO Gastrointestinal Oncology.

Armen Gevorgyan
Fact checked by Armen Gevorgyan MD, Medical Oncologist
Amalya Sargsyan
Medically reviewed by Amalya Sargsyan MD, Medical Oncologist